Zobrazeno 1 - 10
of 46
pro vyhledávání: '"D. Lemeiter"'
Autor:
C. Clavel, C. Valvason, Liliane Laroche, Marie-Christophe Boissier, T. Begue, D. Lemeiter, Natacha Bessis
Publikováno v:
Human gene therapy. 18(6)
Intraarticular gene transfer with adeno-associated viral (AAV) vectors may allow efficient therapeutic transgene expression within the joint in diseases such as rheumatoid arthritis (RA), allowing high expression of the protein within the joint, prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3ee64a041eca09ea763e03625216f6
https://pubmed.ncbi.nlm.nih.gov/17532727
https://pubmed.ncbi.nlm.nih.gov/17532727
Autor:
Gaëlle Clavel, O. Schischmanoff, Luca Semerano, Eric Assier, D. Lemeiter, MC Boissier, Anne Denys
Publikováno v:
Annals of the Rheumatic Diseases. 74:932.2-932
Background Cardiovascular disease (CVD) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Increased cardiovascular risk in RA is attributed to both traditional risk factors and systemic inflammation over a long period. Limited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91538eb0e7c696c3b07bf60b66f634a1
https://doi.org/10.1136/annrheumdis-2015-eular.4263
https://doi.org/10.1136/annrheumdis-2015-eular.4263
Autor:
M.C. deVernejoul, D. Lemeiter, M.C. Boissier, Addolorata Corrado, Martine Cohen-Solal, N. Saidenberg-Kermanac'h
Publikováno v:
Bone. 35(5)
Introduction: Rheumatoid arthritis (RA) is associated with focal and systemic bone loss involving cytokines such as RANKL and TNF-α. RANK-L promotes focal and systemic osteoporosis, whereas osteoprotegerin (OPG) inhibits bone resorption. Although an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352cfa06b4ab924390f02c211fa8722b
https://pubmed.ncbi.nlm.nih.gov/15542046
https://pubmed.ncbi.nlm.nih.gov/15542046
Publikováno v:
Annals of the Rheumatic Diseases. 71:483.3-484
Background Interleukin (IL)-35 is a novel interleukin described as an immunosuppressive cytokine specifically produced by CD4+FoxP3+ regulatory T (Tregs) cells but not by conventional T cells. Objectives Since Tregs play a major role in autoimmunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dba93496a38e6a3c4b98f97294ad549
https://doi.org/10.1136/annrheumdis-2012-eular.2986
https://doi.org/10.1136/annrheumdis-2012-eular.2986
Publikováno v:
Annals of the Rheumatic Diseases. 71:485.1-485
Background Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for blocking IL-6 in this disease mainly lays on the pro-inflammator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abeb58641c4d94b40442ed5fa5857aae
https://doi.org/10.1136/annrheumdis-2012-eular.2990
https://doi.org/10.1136/annrheumdis-2012-eular.2990
Autor:
Luca Semerano, Yves-Marie Pers, Allan Thiolat, N Bessis, Pierre Portales, Jerome Biton, D. Lemeiter, Pascale Louis-Plence, Marie-Christophe Boissier, Christian Jorgensen, Patrice Decker
Publikováno v:
Annals of the Rheumatic Diseases. 72:A16.3-A17
Background and Objectives Studies have demonstrated the clinical efficacy of tocilizumab, a humanised anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for blocking IL-6 in this disease mainly lays on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa1839dc90485998b4801d431f1a1c3d
https://doi.org/10.1136/annrheumdis-2013-203216.10
https://doi.org/10.1136/annrheumdis-2013-203216.10
Publikováno v:
Annals of the Rheumatic Diseases. 71:A13.1-A13
Backgroundand objectives Interleukin (IL)-35 is a novel interleukin described as an immunosuppressive cytokine specifically produced by CD4+FoxP3+ regulatory T (Tregs) cells but not by conventional T cells. Since Tregs play a major role in autoimmuni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9d3276efad8b33735933fc850b73ac
https://doi.org/10.1136/annrheumdis-2011-201230.29
https://doi.org/10.1136/annrheumdis-2011-201230.29
Publikováno v:
Annals of the Rheumatic Diseases. 71:A6.2-A7
Backgroundand objectives Studies have demonstrated the clinical efficacy of tocilizumab, a humanised anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for blocking IL-6 in this disease mainly lays on the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55b641c8202e54997183db77a21ce451
https://doi.org/10.1136/annrheumdis-2011-201230.14
https://doi.org/10.1136/annrheumdis-2011-201230.14
Autor:
N Bessis, Géraldine Grouard-Vogel, D. Lemeiter, M. A. Laborie, Laure Delavallée, Jérôme Biton, MC Boissier, Luca Semerano
Publikováno v:
Annals of the Rheumatic Diseases. 70:A43-A43
Background and objectives Tumour necrosis factor (TNF) is a critical cytokine in rheumatoid arthritis. The authors recently demonstrated the efficacy of active immunotherapy against TNF (TNF-K) in a human TNF transgenic (TTg) mouse model of arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ffbc254851fdaac2033a6acc5b70ca0
https://doi.org/10.1136/ard.2010.148981.2
https://doi.org/10.1136/ard.2010.148981.2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.